Paul McKenzie is chief operating officer of CSL Limited, a global biotechnology company with a portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. He leads the company’s global end-to-end operations organization and its accompanying strategy for achieving safety, quality, reliability, and innovation. He has responsibility for CSL Plasma and its network of more than 260 collection centers in the United States and Europe, as well as manufacturing, quality, engineering, environment, health and safety, business resiliency, business technology, supply chain, procurement, business services, and enterprise excellence. In July he took on additional responsibilities, including Seqirus, one of the world’s largest influenza vaccine providers and a partner in pandemic preparedness.

Prior to joining CSL, Dr. McKenzie was executive vice president of Pharmaceutical Operations & Technology at Biogen, responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering. He also has held senior roles in R&D and manufacturing for Johnson & Johnson, Bristol-Myers Squibb, and Merck, earning a reputation as a patient-focused business leader.

Dr. McKenzie was elected to the NAE earlier this year. He has served on numerous professional and academic boards, including the board of trustees for the Illinois Institute of Technology and the Society for Biological Engineering.

He holds a BS from the University of Pennsylvania and a PhD from Carnegie Mellon University, both in chemical engineering.